One-Step Method for Instant Generation of Advanced Allogeneic NK Cells.

One-Step Method for Instant Generation of Advanced Allogeneic NK Cells.
复制标题

DOI:
10.1002/advs.201800447
复制
发表时间:
2018-11
期刊:
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
影响因子:
--
通讯作者:
Won YW
Won YW
中科院分区:
其他
文献类型:
--
作者:
Lee DY;Lim KS;Valencia GM;Jung M;Bull DA;Won YW

文献摘要

参考文献

相似文献

传统的组合抗癌疗法已经显示出有希望的结果;尽管如此,对开发新方法以加强和可能合并化疗和免疫疗法的重大兴趣仍然存在。在这里,提出了一种新的一步法,通过在免疫细胞表面自发和快速掺入疏水化抗体-药物缀合物(ADC),立即将免疫细胞修饰为靶向形式的化学免疫疗法。这种方法的治疗目的包括靶向递送有效的化疗剂以避免不良反应,增强输注的免疫细胞向肿瘤部位的动员,并保持免疫细胞对肿瘤细胞的强烈细胞毒性活性。使用本研究中的策略将疏水化ADC包埋在免疫细胞膜上提供了非侵入性、无毒和均质的修饰,其用靶向癌细胞的高效细胞毒性药物瞬时武装免疫细胞。由此产生的具有ADC的表面工程化免疫细胞显著抑制肿瘤生长,并通过组合抗癌效应驱动靶癌细胞的根除。这种新的策略允许方便和及时地在单个免疫细胞上制备先进的化学免疫疗法,以治疗各种类型的癌症。
Conventional combinatorial anticancer therapy has shown promising outcomes; still, a significant interest in developing new methods to reinforce and possibly merge chemotherapy and immunotherapy persists. Here, a new one‐step method that immediately modifies immune cells into a targeted form of chemoimmunotherapy through spontaneous and rapid incorporation of hydrophobized antibody–drug conjugates (ADCs) on the surface of immune cells is presented. Therapeutic objectives of this approach include targeted delivery of a potent chemotherapeutic agent to avoid adverse effects, enhancing the mobilization of infused immune cells toward tumor sites, and preserving the intense cytotoxic activities of immune cells against tumor cells. The embedding of hydrophobized ADCs on the immune cell membrane using the strategy in this study provides noninvasive, nontoxic, and homogenous modifications that transiently arm immune cells with highly potent cytotoxic drugs targeted toward cancer cells. The resulting surface‐engineered immune cells with ADCs significantly suppress the tumor growth and drive the eradication of target cancer cells through combinatorial anticancer effects. This novel strategy allows convenient and timely preparation of advanced chemoimmunotherapy on a single immune cell to treat various types of cancer.
DOI: 10.1097/ppo.0b013e3181eb5066
发表时间: 2010-07
期刊: Cancer journal (Sudbury, Mass.)
影响因子: --
作者:
Emens LA
通讯作者: Emens LA
DOI: 10.2217/imt.11.131
发表时间: 2011-12
期刊: Immunotherapy
影响因子: 2.8
作者:
Geller MA;Miller JS
通讯作者: Miller JS
DOI: 10.1158/0008-5472.can-05-4489
发表时间: 2006-04-15
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Erickson, HK;Park, PU;Blättler, WA
通讯作者: Blättler, WA
在合成生物学时代,用于癌症免疫疗法的过继T细胞转移。
DOI: 10.1016/j.immuni.2013.07.002
发表时间: 2013-07-25
期刊: Immunity
影响因子: 32.4
作者:
Kalos M;June CH
通讯作者: June CH
DOI: 10.15252/emmm.201607485
发表时间: 2017-09
影响因子: 11.1
作者:
Hartmann J;Schüßler-Lenz M;Bondanza A;Buchholz CJ
通讯作者: Buchholz CJ